The progression-free survival was reported following Prostate Cancer Working Group (PCWG3), wherein the time from the start of therapy to the date of first PSA had an increase of ≥25% and ≥2 ng/ml from nadir or date of start systemic treatment. Here, KLK3 is linked to prostate carcinoma.